Exogenesis COVID-19 Deactivation Challenge Trial Reaches Primary Endpoints

October 16, 2020

Exogenesis COVID-19 Deactivation Challenge Trial Reaches Primary Endpoints

Exogenesis Corporation announced that it had acheived the primary endpoints of trapping and deactivating SARS-CoV-2 in simulated real-world exposures in a series of challenge tests for the Exogenesis Surgical Mask (ESM), a protective nose and mouth covering for healthcare workers and patients involved in medical and surgical procedures. Any innovation that enhances patient and clinician safety is welcome news to Yourway and our clients trying to conduct clinical trials during the pandemic.

Back to Index

Media

Upcoming Event

Media

Articles

Staying Ahead of COVID-19

Open chat

Hello! How can I help you?